Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
Study Details
Study Description
Brief Summary
This phase II trial compares the effect of ipilimumab and nivolumab combination with cabozantinib, ipilimumab, and nivolumab combination in treating patients >= 18 years old with soft tissue sarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is a chemotherapy drug that works by blocking the formation of new blood vessels in tumors, something tumors need to do to grow. Adding cabozantinib to the combination of ipilimumab and nivolumab may be effective in slowing the growth of soft tissue sarcoma tumors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
PRIMARY OBJECTIVE:
- Assess progression free survival (PFS) of ipilimumab + nivolumab versus (vs.) the cabozantinib + nivolumab + ipilimumab combination in patients with refractory soft tissue sarcoma (STS) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
SECONDARY OBJECTIVES:
-
Evaluate the response rate (complete response [CR]+partial response [PR]) of ipilimumab + nivolumab vs. the cabozantinib + nivolumab + ipilimumab combination.
-
Evaluate the response rate (CR+PR) of cabozantinib + ipilimumab + nivolumab in (crossover) patients whose disease has progressed on ipilimumab + nivolumab doublet therapy.
-
Assess the number of tumor-infiltrating CD8+ T cells in tumor biopsies before and after treatment.
EXPLORATORY OBJECTIVES:
-
Measure tumor-infiltrating CD3+ T cells and CD68+ macrophages in biopsy specimens.
-
Investigate whether response is associated with genetic aberrations and/or tumor mutational burden.
-
Analyze T cell receptor (TCR) signaling in tumor-infiltrating T cells. IV. Analyze total MET and activated MET (p1235-MET) in biopsy specimens before and after study treatment and evaluate molecular target engagement by cabozantinib (as shown by a lower phosphorylated [p]MET/MET ratio).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive nivolumab intravenously (IV) and ipilimumab IV on study. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) scans throughout the trial, tumor biopsies on study, and collection of blood throughout the trial.
ARM II: Patients receive cabozantinib orally (PO), nivolumab IV, and ipilimumab IV on study. Patients also undergo CT or MRI scans throughout the trial, tumor biopsies on study, and collection of blood throughout the trial.
Patients are followed for 30 days after completion of study treatment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Arm I (nivolumab, ipilimumab) Patients receive nivolumab IV and ipilimumab IV on study. Patients also undergo CT or MRI scans throughout the trial, tumor biopsies on study, and collection of blood throughout the trial. |
Procedure: Biopsy
Undergo biopsy
Other Names:
Procedure: Biospecimen Collection
Undergo collection of blood
Other Names:
Procedure: Computed Tomography
Undergo CT
Other Names:
Biological: Ipilimumab
Given IV
Other Names:
Procedure: Magnetic Resonance Imaging
Undergo MRI
Other Names:
Biological: Nivolumab
Given IV
Other Names:
|
| Experimental: Arm II (cabozantinib, nivolumab, ipilimumab) Patients receive cabozantinib PO, nivolumab IV, and ipilimumab IV on study. Patients also undergo CT or MRI scans throughout the trial, tumor biopsies on study, and collection of blood throughout the trial. |
Procedure: Biopsy
Undergo biopsy
Other Names:
Procedure: Biospecimen Collection
Undergo collection of blood
Other Names:
Drug: Cabozantinib
Given PO
Procedure: Computed Tomography
Undergo CT
Other Names:
Biological: Ipilimumab
Given IV
Other Names:
Procedure: Magnetic Resonance Imaging
Undergo MRI
Other Names:
Biological: Nivolumab
Given IV
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Progression-free survival (PFS) [Up to 30 days after completion of study treatment]
Will be assessed using Response Evaluation Criteria in Solid Tumors version (v)1.1. The primary analysis will be a logrank test and will be performed once 52 PFS events have been observed. In addition, a single interim futility analysis (Wieand rule) will be performed at 50% information (26 PFS events).
Secondary Outcome Measures
- Objective response rate [Up to 30 days after completion of study treatment]
Defined as complete response or partial response by RECIST v1.1. Response rates within the two study arms will be (separately) reported and will be directly compared using a two-sample test of proportions. In addition, will report the rate of objective response to cabozantinib + ipilimumab + nivolumab triplet therapy in patients who have crossed over after their disease progressed on ipilimumab + nivolumab doublet.
- Number of tumor-infiltrating CD8+ T cells [Baseline and cycle 2, day 22 (C2D22)]
Will be evaluated in tumor biopsies before and after treatment. Changes between paired samples will be interpreted as being likely treatment-induced if they exceed the sampling, biological, and technical variabilities determined for the assay. Unpaired baseline and post-treatment measurements may also be assessed for correlation with response, which will shed light on possible CD8+ T cell density or infiltration requirements that could inform future trial designs.
Other Outcome Measures
- Tumor-infiltrating CD3+ T cells and CD68+ macrophages [Baseline and C2D22]
Will be evaluated in tumor biopsies. Non-parametric analyses will be used.
- Genetic aberrations and/or tumor mutational burden [Up to 30 days after completion of study treatment]
Will investigate whether response is associated with genetic aberrations and/or tumor mutational burden. Non-parametric analyses will be used.
- T cell receptor signaling in tumor-infiltrating T cells [Baseline and C2D22]
Will be evaluated in tumor biopsies. Non-parametric analyses will be used.
- Total MET and activated MET [Baseline and C2D22]
Will be evaluated in biopsy specimens before and after study treatment. Will evaluate molecular target engagement by cabozantinib (as shown by a lower phosphorylated [p]MET/MET ratio). Non-parametric analyses will be used.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have histologically or cytologically confirmed metastatic undifferentiated pleomorphic sarcoma (UPS), extraskeletal myxoid chondrosarcoma (EMC), liposarcoma (LPS) or non-uterine leiomyosarcoma (LMS)
-
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) by chest x-ray or as >= 10 mm (>= 1 cm) with CT scan, MRI, or calipers by clinical exam. Disease will be measured by RECISTv1.1
-
Patients with prior treatment with MET or VEGFR inhibitors are allowed. However, prior cabozantinib-treated patients will not be allowed. Prior ipilimumab in combination with nivolumab-treated patients will not be allowed
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Absolute neutrophil count >= 1,000/mcL
-
Platelets >= 75,000/mcL
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
-
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
-
Creatinine =< institutional ULN OR glomerular filtration rate (GFR) >= 50 mL/min/1.73 m2 unless data exist supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2
-
Serum albumin >= 2.8g/dL
-
Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
-
Urine protein/creatinine ratio (UPCR) =< 1
-
Patients with a requirement for steroid treatment or other immunosuppressive treatment: Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and undetectable HCV viral load 12 or more weeks after treatment completion. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression >= 1 month after treatment of the brain metastases. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first 2 cycles of therapy
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Patients must be willing to provide blood specimens and undergo biopsies for research purposes
-
Patients with baseline blood pressure (BP) lower than 140 mmHg (systolic) and 90 mmHg (diastolic). Patients on > 2 anti-hypertensive agents will be excluded
-
Human immunodeficiency virus (HIV)-infected patients on effective combination antiretroviral therapy are eligible as long as HIV is well-controlled and there is undetectable viral load within 6 months. For these patients, an HIV viral load test must be completed within 28 days prior to enrollment
-
The effects of nivolumab, ipilimumab, and cabozantinib on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP (defined as any female who has experienced menarche and who has not undergone surgical sterilization [hysterectomy or bilateral oophorectomy] or who is not postmenopausal) should use an adequate method to avoid pregnancy for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding
-
Men who are sexually active with women of child-bearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year. Men receiving cabozantinib and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 4 months after the last dose of investigational product. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
Patients who have not recovered from clinically significant adverse events of their most recent therapy/intervention prior to enrollment
-
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia, stable hyperthyroidism on replacement therapy, type-1 diabetes, well-controlled insulin, and non-clinically significant toxicities at the discretion of the study Principal Investigator
-
Patients who are receiving any other investigational agents
-
Eligibility of subjects receiving any medications or substances known to affect or with the potential to affect the activity of cabozantinib will be determined following review of their cases by the Principal Investigator. Patients who are taking enzyme-inducing anticonvulsant agents are not eligible
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, or ipilimumab
-
Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's Wort) are not allowed for this study. Because the lists of these agents are constantly changing, frequently updated lists available at http://medicine.iupui.edu/clinpharm/ddis/table.asp or other reliable resources will be consulted. Patients who need to come off CYP3A4 inhibitors/inducers should adhere to a washout period of at least 5 times the half-life of the CYP3A4 inhibitors and 14 days of CYP3A4 inducers
-
Patients with any other significant condition(s) that would make this protocol unreasonably hazardous are ineligible. Patients with uncontrolled intercurrent illness or clinical evidence of an active infection at the time of enrollment are ineligible
-
Pregnant women are excluded from this study because cabozantinib is a receptor kinase inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib in combination with nivolumab and ipilimumab, breastfeeding should be discontinued if the mother is treated with cabozantinib. These potential risks may also apply to other immunotherapeutic agents (ipilimumab and nivolumab) used in this study
-
Patients that require concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel). Low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted. (Please note that there may be cases in which patients on study require anticoagulation for deep vein thrombosis/pulmonary embolism [DVT/PE] management; this does not necessitate taking the patient off study)
-
Patients with any of the following within 12 weeks prior to the first dose of cabozantinib: gastrointestinal bleeding, hemoptysis or pulmonary hemorrhage, radiographic evidence of cavitating pulmonary lesion(s), evidence of tumor invasion of the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum, or anus), or any evidence of endotracheal or endobronchial tumor or encasement of any major blood vessels
-
The patient is unable to swallow tablets
-
The patient has a corrected QT interval calculated by the Fridericia formula (QTcF) < 470 ms within 28 days before enrollment
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: A P Chen, National Cancer Institute LAO
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NCI-2023-03149
- NCI-2023-03149
- 10556
- 10556